Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Antithrombin-III as an early prognostic factor in children with acute lung injury

급성 폐손상 소아 환자에서 조기 예후 인자로서의 antithrombin-III

  • Lee, Young Seung (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kim, Seonguk (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Kang, Eun Kyeong (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Park, June Dong (Department of Pediatrics, Seoul National University College of Medicine)
  • 이영승 (서울대학교 의과대학 소아과학교실) ;
  • 김성국 (서울대학교 의과대학 소아과학교실) ;
  • 강은경 (서울대학교 의과대학 소아과학교실) ;
  • 박준동 (서울대학교 의과대학 소아과학교실)
  • Received : 2007.02.06
  • Accepted : 2007.04.02
  • Published : 2007.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : To evaluate the potential prognostic value of the antithrombin-III (AT-III) level in the children with acute lung injury (ALI), we analyzed several early predictive factors of death including AT-III level at the onset of ALI and compared the relative risk of them for mortality. Methods : Over a 18-month period, a total of 198 children were admitted to our pediatric intensive care unit and 21 mechanically ventilated patients met ALI criteria, as defined by American-European consensus conference, i.e., bilateral pulmonary infiltrates and $PaO_2/FiO_2$ lower than 300 without left atrial hypertension. Demographic variables, hemodynamic and respiratory parameters, underlying diseases, as well as Pediatric Risk of Mortality-III (PRISM-III) scores and Lung Injury Score (LIS) at admission were collected. AT-III levels were measured within 3 hours after admission. These variables were compared between survivors and non-survivors and entered into a multiple logistic regression analysis to evaluate their independent prognostic roles. Results : The overall mortality rate was 38.1% (8/21). Non-survivors showed lower age, lower lung compliance, higher PEEP, higher oxygenation index (OI), lower arterial pH, lower $PaO_2/FiO_2$, higher PRISM-III score and LIS, and lower AT-III level. PRISM-III score, LIS, OI and decreased AT-III level (less than 70%) were independently associated with a risk of death and the odds ratio of decreased AT-III level for mortality is 2.75 (95% confidence interval; 1.28-4.12) Conclusion : These results suggest that the decreased level of AT-III is an important prognostic factor in children with ALI and the replacement of AT-III may be considered as an early therapeutic trial.

목 적 : 급성 폐손상이 있는 소아에서 혈액 응고 과정에서 중요한 역할을 하는 AT-III의 예후인자로서의 의미를 확인하고자 대상 환자에서 진단 초기의 AT-III 값을 측정하고 사망여부에 따라 AT-III 값을 비교 분석하고 지금까지 알려진 여러 예후인자들과 비교 분석하였다. 방 법 : 2004년 6월부터 2005년 12월까지 18개월 동안 서울대학교병원 소아중환자실에 입원한 198명의 환자 중 급성 폐손상의 정의를 만족하고 기계적 환기요법을 받은 21명의 환자를 대상으로 인구의학적인 변수와 기저질환, 초기 안정화 이후의 호흡지수들, 기계적 환기요법의 여러 설정 등을 측정하였다. 중환자실 입원 24시간 이내의 PRISM-III 점수, LIS 점수를 측정하였고 입원 3시간 내의 AT-III 값을 측정하였다. 사망여부에 따라 두 군으로 분류한 후 예후인자를 비교분석하였고, PRISM-III 값과 AT-III 값에 대해서는 상관관계와 회귀분석을 함께 시행하였다. 단변수 분석에서 사망여부에 따라 통계적으로 유의한 변수에 대해서 중회귀 분석을 시행하여 상대위험도를 측정하였다. 결 과 : 18개월 동안 198명이 입원하였고 21명의 환자가 진단기준을 만족하였다. 남자가 13명(61.9%)였고 연령은 5(1-14)세였다. 급성 폐손상이 발생한 장소가 병원이 아닌 경우가 33.3%였고 기저질환이 폐 병변인 경우가 66.7%였다. 대상 환자 중 AT-III 값이 70% 이하인 경우가 10명(42.9%)이였고 8명의 환자가 사망하여 사망률은 38.1%였다. 사망에 따른 두 군 간의 비교에서 초기 안정화 이후 동맥혈 pH와 $PaO_2/FiO_2$는 사망한 환자군에서 유의하게 더 낮았고, OI와 호기말 양압은 사망한 환자군에서 유의하게 더 높았다. 폐 유순도는 사망한 환자군에서 유의하게 더 낮았다. LIS와 PRISM-III는 사망한 환자군에서 모두 유의하게 높았고 AT-III는 사망한 환자군에서 유의하게 더 낮았다. AT-III와 PRISM-III 값은 유의한 상관관계를 보였다. 중회귀분석에서 PRISM-III, LIS, OI는 모두 다른 변수에 독립적으로 유의한 사망의 위험인자였으며 70% 미만으로 정의한 AT-III 감소는 급성 폐손상 환자에서 다른 변수에 독립적으로 사망의 유의한 위험인자였다(OR 2.725, 95% CI 1.284-4.119). 결 론 : 급성 폐손상으로 기계적 환기요법을 시행 받은 소아환자를 대상으로 한 본 연구에서 초기 AT-III 값은 PRISM-III 값과 유의한 상관관계를 보였으며, 또한 사망한 환자군에서 AT-III 값이 유의하게 더 낮았고 이것은 다른 위험인자의 영향을 보정한 상태에서도 독립적인 사망의 위험인자였다. 이로써 AT-III가 급성 폐손상의 유의한 조기 예후 예측인자라는 것을 확인하였으며 향후 급성 폐손상/급성 호흡부전증후군 환자에서 응고장애를 정상화 할 수 있는 처치들이 예후를 향상시킬 수 있을 가능성을 제시하였다.

Keywords

References

  1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994;149:818-24 https://doi.org/10.1164/ajrccm.149.3.7509706
  2. Pelosi P, Caironi P, Gattinoni L. Pulmonary and extrapulmonary forms of acute respiratory distress syndrome. Semin Respir Crit Care Med 2001;22:259-68 https://doi.org/10.1055/s-2001-15783
  3. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992;145:1016-22 https://doi.org/10.1164/ajrccm/145.5.1016
  4. Neff MJ, Rubenfeld GD. Clinical epidemiology of acute lung injury. Semin Respir Crit Care Med 2001;22:237-46 https://doi.org/10.1055/s-2001-15781
  5. Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med 1996; 24:743-52 https://doi.org/10.1097/00003246-199605000-00004
  6. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3 https://doi.org/10.1164/ajrccm/138.3.720
  7. Gunther A, Walmrath D, Grimminger F, Seeger W. Pathophysiology of acute lung injury. Semin Respir Crit Care Med 2001;22:247-58 https://doi.org/10.1055/s-2001-15782
  8. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new traget in therapeutic studies of acute lung injury or pneumonia-A review. Crit Care Med 2006;34:871-7 https://doi.org/10.1097/01.CCM.0000201882.23917.B8
  9. Levi M, ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999;341:586-92 https://doi.org/10.1056/NEJM199908193410807
  10. Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992;101:816-23 https://doi.org/10.1378/chest.101.3.816
  11. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114-20 https://doi.org/10.1172/JCI116934
  12. Biemond BJ, Levi M, ten Cate H, Soule HR, Morris LD, Foster DL, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa. Thromb Haemost 1995;73: 223-30
  13. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, et al. Blood-borne tissue factor: Another view of thrombosis. Proc Natl Acad Sci U S A 1999;96:2311-5 https://doi.org/10.1073/pnas.96.5.2311
  14. van der Poll T, de Jonge E, Levi M. Regulatory role of cytokines in disseminated intravacular coagulation. Semin Thromb Hemost 2001;27:639-52
  15. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992;145:1016- 22 https://doi.org/10.1164/ajrccm/145.5.1016
  16. Miller DL, Welty-Wolf K, Carraway MS, Ezban M, Ghio A, Suliman H, et al. Extrinsic coagulation blockade attenuates lung injury and proinflammatory cytokine release after intratracheal lipopolysaccharide. Am J Respir Cell Mol Biol 2002; 26:650-8 https://doi.org/10.1165/ajrcmb.26.6.4688
  17. Levi M, van der Poll T, ten Cate H, Kuipers B, Biemond BJ, Jansen HM, et al. Differential effects of anti-cytokine treatment on bronchoalveolar hemostasis in endotoxemic chimpanzees. Am J Respir Crit Care Med 1998;158:92-8 https://doi.org/10.1164/ajrccm.158.1.9709007
  18. Okajima K. Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation. Blood Coagul Fibrinolysis 1998;9 Suppl 2:S25-37
  19. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49 https://doi.org/10.1056/NEJM200005043421806
  20. Doyle RL, Szaflarski N, Modin GW, Wiener-Kronish JP, Matthay MA. Identification of patients with acute lung injury: predictors of mortality. Am J Respir Crit Care Med 1995; 152:1818-24 https://doi.org/10.1164/ajrccm.152.6.8520742
  21. Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU: Comorbid conditions, age, etiology, and hospital outcome. Am J Respir Crit Care Med 1998;157:1159-64. https://doi.org/10.1164/ajrccm.157.4.9704088
  22. Vieillard-Baron A, Girou E, Valente E, Brun-Buisson C, Jardin F, Lemaire F, et al. Predictors of mortality in acute respiratory distress syndrome. Focus On the role of right heart catheterization. Am J Respir Crit Care Med 2000;161: 1597-601
  23. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E, Umberger R, et al. Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107:1062-73 https://doi.org/10.1378/chest.107.4.1062
  24. Shorr AF, Thomas SJ, Alkins SA, Fitzpatrick TM, Ling GS. D-dimer correlates with pro-inflammatory cytokines levels and outcomes in critically ill patients. Chest 2002;121:1262-8 https://doi.org/10.1378/chest.121.4.1262
  25. Siemiatkowski A, Kloczko J, Galar M, Czaban S. von Willebrand factor antigen as a prognostic marker in posttraumatic acute lung injury. Haemostasis 2000;30:189-95